We have developed a MUC1 antigen-based antitumor vaccine loaded on alum colloid encapsulated insideβ-glucan particles(GP-Al).The constructed vaccine induced strong MUC1 antigen specific Ig G antibody titers and enhan...We have developed a MUC1 antigen-based antitumor vaccine loaded on alum colloid encapsulated insideβ-glucan particles(GP-Al).The constructed vaccine induced strong MUC1 antigen specific Ig G antibody titers and enhanced CD^(8+)T cells cytotoxic effect to kill tumor cells.These results indicated that GP-Al can be served as an efficient delivery system and adjuvant for the development of cancer vaccines especially small molecule antigens based cancer vaccines.展开更多
基金supported by the National Natural Science Foundation of China(No.22077068)the National Key R&D Program of China(No.2018YFA0507204)+2 种基金the NCC Fund(No.NCC2020FH12)the Natural Science Foundation of Tianjin(No.19JCQNJC05300)the Fundamental Research Funds for the Central Universities。
文摘We have developed a MUC1 antigen-based antitumor vaccine loaded on alum colloid encapsulated insideβ-glucan particles(GP-Al).The constructed vaccine induced strong MUC1 antigen specific Ig G antibody titers and enhanced CD^(8+)T cells cytotoxic effect to kill tumor cells.These results indicated that GP-Al can be served as an efficient delivery system and adjuvant for the development of cancer vaccines especially small molecule antigens based cancer vaccines.
